1. Chidambaranathan-Reghupaty, S., P.B. Fisher, and D. Sarkar, Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res, 2021. 149: p. 1-61.
2. Kulik, L. and H.B. El-Serag, Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 2019. 156(2): p. 477-491.e1.
3. Llovet, J.M., et al., Hepatocellular carcinoma. Nat Rev Dis Primers, 2021. 7(1): p. 6.
4. El-Serag, H.B. and K.L. Rudolph, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007. 132(7): p. 2557-76.
5. Hartke, J., M. Johnson, and M. Ghabril, The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol, 2017. 34(2): p. 153-159.
6. Leung, T.W., et al., Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer, 2002. 94(6): p. 1760-9.
7. Greene, F., et al., AJCC Cancer Staging Handbook–7th ed., 2010. American Joint Committee on Cancer, Chicago, IL, USA, 2009.
8. Han, K. and J.H. Kim, Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol, 2015. 21(36): p. 10327-35.
9. Volk, M.L. and J.A. Marrero, Early detection of liver cancer: diagnosis and management. Current gastroenterology reports, 2008. 10(1): p. 60-66.
10. Grandhi, M.S., et al., Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol, 2016. 25(2): p. 74-85.
11. Murphy, D.J., A. Aghayev, and M.L. Steigner, Vascular CT and MRI: a practical guide to imaging protocols. Insights Imaging, 2018. 9(2): p. 215-236.
12. Vernuccio, F., et al., CT and MR imaging evaluation of living liver donors. Abdom Radiol (NY), 2021. 46(1): p. 17-28.
13. Gnutzmann, D., et al., Transvascular therapy of Hepatocellular Carcinoma (HCC), status and developments. Minim Invasive Ther Allied Technol, 2018. 27(2): p. 69-80.
14. Liu, C.Y., K.F. Chen, and P.J. Chen, Treatment of Liver Cancer. Cold Spring Harb Perspect Med, 2015. 5(9): p. a021535.
15. Couri, T. and A. Pillai, Goals and targets for personalized therapy for HCC. Hepatol Int, 2019. 13(2): p. 125-137.
16. Johnston, M.P. and S.I. Khakoo, Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol, 2019. 25(24): p. 2977-2989.
17. Llovet, J.M., et al., Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol, 2018. 15(10): p. 599-616.
18. Xu, F., et al., Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res, 2018. 37(1): p. 110.
19. Rijsewijk, F., et al., The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell, 1987. 50(4): p. 649-57.
20. Nüsslein-Volhard, C. and E. Wieschaus, Mutations affecting segment number and polarity in Drosophila. Nature, 1980. 287(5785): p. 795-801.
21. Nusse, R., et al., Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature, 1984. 307(5947): p. 131-6.
22. MacDonald, B.T., et al., Disulfide bond requirements for active Wnt ligands. Journal of Biological Chemistry, 2014. 289(26): p. 18122-18136.
23. Routledge, D. and S. Scholpp, Mechanisms of intercellular Wnt transport. Development, 2019. 146(10).
24. Biechele, S., B.J. Cox, and J. Rossant, Porcupine homolog is required for canonical Wnt signaling and gastrulation in mouse embryos. Developmental biology, 2011. 355(2): p. 275-285.
25. Strutt, D., et al., Structure–function dissection of the frizzled receptor in Drosophila melanogaster suggests different mechanisms of action in planar polarity and canonical Wnt signaling. Genetics, 2012. 192(4): p. 1295-1313.
26. Huang, H.C. and P.S. Klein, The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol, 2004. 5(7): p. 234.
27. DeBruine, Z.J., H.E. Xu, and K. Melcher, Assembly and architecture of the Wnt/β-catenin signalosome at the membrane. Br J Pharmacol, 2017. 174(24): p. 4564-4574.
28. He, X., et al., LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development, 2004. 131(8): p. 1663-77.
29. MacDonald, B.T. and X. He, Frizzled and LRP5/6 receptors for Wnt/β-catenin signaling. Cold Spring Harb Perspect Biol, 2012. 4(12).
30. Tamai, K., et al., A mechanism for Wnt coreceptor activation. Molecular cell, 2004. 13(1): p. 149-156.
31. Ren, Q., J. Chen, and Y. Liu, LRP5 and LRP6 in Wnt Signaling: Similarity and Divergence. Front Cell Dev Biol, 2021. 9: p. 670960.
32. Valenta, T., G. Hausmann, and K. Basler, The many faces and functions of β-catenin. Embo j, 2012. 31(12): p. 2714-36.
33. Niessen, C.M. and C.J. Gottardi, Molecular components of the adherens junction. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2008. 1778(3): p. 562-571.
34. Suryawanshi, A., et al., Modulation of Inflammatory Responses by Wnt/β-Catenin Signaling in Dendritic Cells: A Novel Immunotherapy Target for Autoimmunity and Cancer. Front Immunol, 2016. 7: p. 460.
35. Cadigan, K.M. and M.L. Waterman, TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol, 2012. 4(11).
36. Zhan, T., N. Rindtorff, and M. Boutros, Wnt signaling in cancer. Oncogene, 2017. 36(11): p. 1461-1473.
37. Perugorria, M.J., et al., Wnt-β-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol, 2019. 16(2): p. 121-136.
38. MacDonald, B.T., K. Tamai, and X. He, Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell, 2009. 17(1): p. 9-26.
39. Stamos, J.L., et al., Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6. Elife, 2014. 3: p. e01998.
40. Li, X., M.A. Ortiz, and L. Kotula, The physiological role of Wnt pathway in normal development and cancer. Exp Biol Med (Maywood), 2020. 245(5): p. 411-426.
41. Habas, R., Y. Kato, and X. He, Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1. Cell, 2001. 107(7): p. 843-854.
42. Wang, J., D. Feng, and B. Gao, An Overview of Potential Therapeutic Agents Targeting WNT/PCP Signaling. Handb Exp Pharmacol, 2021. 269: p. 175-213.
43. Lojk, J. and J. Marc, Roles of Non-Canonical Wnt Signalling Pathways in Bone Biology. Int J Mol Sci, 2021. 22(19).
44. Ishitani, T., et al., The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature, 1999. 399(6738): p. 798-802.
45. Cheng, X., et al., Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer. Biomed Pharmacother, 2019. 110: p. 473-481.
46. Clevers, H. and R. Nusse, Wnt/β-catenin signaling and disease. Cell, 2012. 149(6): p. 1192-205.
47. Polakis, P., Wnt signaling in cancer. Cold Spring Harb Perspect Biol, 2012. 4(5).
48. Reya, T. and H. Clevers, Wnt signalling in stem cells and cancer. Nature, 2005. 434(7035): p. 843-850.
49. Kinzler, K.W. and B. Vogelstein, Lessons from hereditary colorectal cancer. Cell, 1996. 87(2): p. 159-170.
50. Takeda, H., et al., Human sebaceous tumors harbor inactivating mutations in LEF1. Nature medicine, 2006. 12(4): p. 395-397.
51. Katoh, M., Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). Int J Mol Med, 2018. 42(2): p. 713-725.
52. Bugter, J.M., N. Fenderico, and M.M. Maurice, Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer, 2021. 21(1): p. 5-21.
53. Nusse, R. and H. Clevers, Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell, 2017. 169(6): p. 985-999.
54. MacDonald, B.T., K. Tamai, and X. He, Wnt/β-catenin signaling: components, mechanisms, and diseases. Developmental cell, 2009. 17(1): p. 9-26.
55. Duchartre, Y., Y.M. Kim, and M. Kahn, The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol, 2016. 99: p. 141-9.
56. Zhang, Y. and X. Wang, Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol, 2020. 13(1): p. 165.
57. Lu, J., et al., Structure–activity relationship studies of small-molecule inhibitors of Wnt response. Bioorganic & medicinal chemistry letters, 2009. 19(14): p. 3825-3827.
58. Dodge, M.E., et al., Diverse chemical scaffolds support direct inhibition of the membrane-bound O-acyltransferase porcupine. Journal of Biological Chemistry, 2012. 287(27): p. 23246-23254.
59. Steinhart, Z., et al., Genome-wide CRISPR screens reveal a Wnt–FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Nature medicine, 2017. 23(1): p. 60-68.
60. Choi, J., et al., In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors. Bioorganic & Medicinal Chemistry Letters, 2018. 28(6): p. 1116-1121.
61. Huang, S.-M.A., et al., Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature, 2009. 461(7264): p. 614-620.
62. Lau, T., et al., A novel tankyrase small-molecule inhibitor suppresses APC mutation–driven colorectal tumor growth. Cancer research, 2013. 73(10): p. 3132-3144.
63. Shao, J., et al., Prostaglandin E2 stimulates the β-catenin/T cell factor-dependent transcription in colon cancer. Journal of Biological Chemistry, 2005. 280(28): p. 26565-26572.
64. Thun, M.J., S.J. Henley, and C. Patrono, Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst, 2002. 94(4): p. 252-66.
65. Smalley, W.E. and R.N. DuBois, Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol, 1997. 39: p. 1-20.
66. Nguyen, C., et al., A small molecule inhibitor of-catenin/CREB-binding protein transcription. Proc. Natl. Acad. Sci. USA, 2004. 101: p. 12682-12687.
67. McWilliams, R.R., et al., A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. 2015, American Society of Clinical Oncology.
68. Pálmer, H.G., et al., Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling. The Journal of cell biology, 2001. 154(2): p. 369-388.
69. Jaiswal, A.S., et al., β-catenin-mediated transactivation and cell–cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene, 2002. 21(55): p. 8414-8427.
70. Ma, J., et al., β-catenin/TCF-1 pathway in T cell development and differentiation. Journal of neuroimmune pharmacology, 2012. 7(4): p. 750-762.
71. Ioannidis, V., et al., The β-catenin–TCF-1 pathway ensures CD4+ CD8+ thymocyte survival. Nature immunology, 2001. 2(8): p. 691-697.
72. Zhu, Y., W. Wang, and X. Wang, Roles of transcriptional factor 7 in production of inflammatory factors for lung diseases. J Transl Med, 2015. 13: p. 273.
73. Roose, J., et al., Synergy between tumor suppressor APC and the β-catenin-Tcf4 target Tcf1. Science, 1999. 285(5435): p. 1923-1926.
74. Van De Wetering, M., et al., The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell, 2002. 111(2): p. 241-250.
75. Shulewitz, M., et al., Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer. Oncogene, 2006. 25(31): p. 4361-4369.
76. Wei, W., et al., Small molecule antagonists of Tcf4/β‐catenin complex inhibit the growth of HCC cells in vitro and in vivo. International journal of cancer, 2010. 126(10): p. 2426-2436.
77. Messeguer, X., et al., PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics, 2002. 18(2): p. 333-4.
78. Farré, D., et al., Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res, 2003. 31(13): p. 3651-3.
79. Castro-Mondragon, J.A., et al., JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res, 2022. 50(D1): p. D165-d173.
80. Sandelin, A., et al., JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res, 2004. 32(Database issue): p. D91-4.
81. Oki, S., et al., ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data. EMBO Rep, 2018. 19(12).
82. Adams, M.D., et al., Complementary DNA sequencing: expressed sequence tags and human genome project. Science, 1991. 252(5013): p. 1651-6.
83. Nagaraj, S.H., R.B. Gasser, and S. Ranganathan, A hitchhiker's guide to expressed sequence tag (EST) analysis. Brief Bioinform, 2007. 8(1): p. 6-21.
84. Parkinson, J. and M. Blaxter, Expressed sequence tags: an overview. Methods Mol Biol, 2009. 533: p. 1-12.
85. 周靖恆, 結合生物資訊的方法探討腫瘤相關基因在人類腎臟癌中的表現, in 分子醫學研究所. 2005, 國立成功大學: 台南市. p. 75.
86. 林珮雯, 探討一個新的胚胎腫瘤幹細胞標記, in 分子醫學研究所. 2016, 國立成功大學: 台南市. p. 72.
87. 葉秀汝, 探討一個新的胚胎腫瘤幹細胞標記, in 分子醫學研究所. 2014, 國立成功大學: 台南市. p. 91.
88. Cheng, S.W., et al., Lin28B is an oncofetal circulating cancer stem cell-like marker associated with recurrence of hepatocellular carcinoma. PLoS One, 2013. 8(11): p. e80053.
89. Hsu, C.C., et al., Identifying LRRC16B as an oncofetal gene with transforming enhancing capability using a combined bioinformatics and experimental approach. Oncogene, 2011. 30(6): p. 654-67.
90. Jho, E.H., et al., Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol, 2002. 22(4): p. 1172-83.
91. Kim, J.S., et al., Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res, 2002. 62(10): p. 2744-8.
92. Clevers, H. and E. Batlle, EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res, 2006. 66(1): p. 2-5.
93. Mansukhani, A., et al., Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J Cell Biol, 2005. 168(7): p. 1065-76.
94. 邱宜凡, 驗證肝癌中Wnt/β-catenin傳遞路徑之新穎基因, in 分子醫學研究所. 2020, 國立成功大學: 台南市. p. 105.
95. Yao, H.H., et al., Follistatin operates downstream of Wnt4 in mammalian ovary organogenesis. Dev Dyn, 2004. 230(2): p. 210-5.
96. Wu, B., S.P. Crampton, and C.C. Hughes, Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity, 2007. 26(2): p. 227-39.
97. Kioussi, C., et al., Identification of a Wnt/Dvl/beta-Catenin --> Pitx2 pathway mediating cell-type-specific proliferation during development. Cell, 2002. 111(5): p. 673-85.
98. Zhang, T., et al., Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res, 2001. 61(24): p. 8664-7.
99. 陳怡文, 結合生物資訊暨實驗篩選以尋找 Wnt/β-catenin 傳遞路徑之新穎基因, in 醫學檢驗生物技術學系碩博士班. 2011, 國立成功大學: 台南市. p. 78.
100. 張瀞云, Zinc Finger Protein 496 在肝癌中是一個有潛力的Wnt/β-catenin 路徑中的標的基因, in 醫學檢驗生物技術學系. 2016, 國立成功大學: 台南市. p. 55.
101. 謝旻樺, 尋找及探討具備腫瘤胚特性之新穎生物標記基因並強調於Zinc Finger Protein 496, in 分子醫學研究所. 2017, 國立成功大學: 台南市. p. 64.
102. 黃孟柔, Wnt/beta-catenin傳遞路徑之新穎基因在肝癌細胞中的生物功能, in 分子醫學研究所. 2019, 國立成功大學: 台南市. p. 79.
103. Johnson, D.S., et al., Genome-wide mapping of in vivo protein-DNA interactions. Science, 2007. 316(5830): p. 1497-502.
104. Pickrell, J.K., et al., False positive peaks in ChIP-seq and other sequencing-based functional assays caused by unannotated high copy number regions. Bioinformatics, 2011. 27(15): p. 2144-6.
105. Jain, D., et al., Active promoters give rise to false positive 'Phantom Peaks' in ChIP-seq experiments. Nucleic Acids Res, 2015. 43(14): p. 6959-68.
106. Li, Y., et al., HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene, 2011. 30(23): p. 2633-43.
107. Xu, L., et al., WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev, 2000. 14(5): p. 585-95.
108. Brannon, M., et al., A beta-catenin/XTcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in Xenopus. Genes Dev, 1997. 11(18): p. 2359-70.
109. He, T.C., et al., Identification of c-MYC as a target of the APC pathway. Science, 1998. 281(5382): p. 1509-12.
110. Jiang, S. and A. Mortazavi, Integrating ChIP-seq with other functional genomics data. Brief Funct Genomics, 2018. 17(2): p. 104-115.
111. Nakato, R. and K. Shirahige, Recent advances in ChIP-seq analysis: from quality management to whole-genome annotation. Brief Bioinform, 2017. 18(2): p. 279-290.